Stay updated with breaking news from Sujalm patel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vanguard Capital Wealth Advisors decreased its stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Free Report) by 13.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,000 shares of the company’s stock after selling 6,000 shares during the period. Vanguard Capital […] ....
Equities analysts expect Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) to announce earnings of ($0.17) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Nautilus Biotechnology’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.18). Nautilus Biotechnology reported earnings per share […] ....
Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 3rd. Analysts expect Nautilus Biotechnology to post earnings of ($0.15) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link. Nautilus Biotechnology […] ....
Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Saturday, Zacks.com reports. According to Zacks, “Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. […] ....
Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) had its price target dropped by stock analysts at The Goldman Sachs Group from $9.00 to $5.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target would suggest a […] ....